Pilot, Randomized, Open-Label, Two-Way Crossover Comparative Bioavailability Study of 40 mg Delayed Release Oral 6Mercaptopurine Versus 100 mg Purinethol in Patients With Crohns Disease.

Trial Profile

Pilot, Randomized, Open-Label, Two-Way Crossover Comparative Bioavailability Study of 40 mg Delayed Release Oral 6Mercaptopurine Versus 100 mg Purinethol in Patients With Crohns Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 May 2010

At a glance

  • Drugs Mercaptopurine (Primary)
  • Indications Crohn's disease
  • Focus Pharmacokinetics
  • Most Recent Events

    • 04 May 2010 Results have been presented at DDW 2010.
    • 31 Mar 2010 Company added as trial sponsor, affiliate as reported by ClinicalTrials.gov.
    • 14 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top